Global Brain Tumor Therapeutics Market - Segmented by Type of Cancer and Therapeutics - Growth, Trends and Forecasts (2018 - 2023)
|出版商||Mordor Intelligence LLP||商品編碼||391488|
|出版日期||內容資訊||英文 111 Pages
|全球腦瘤治療藥市場:成長，趨勢，預測 Global Brain Tumor Therapeutics Market - Segmented by Type of Cancer and Therapeutics - Growth, Trends and Forecasts (2018 - 2023)|
|出版日期: 2018年02月08日||內容資訊: 英文 111 Pages||
The global brain tumor therapeutics market has been estimated to reach USD 2.74 billion in 2023. The market is expected to register a CAGR of 11% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements. Developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are other impact rendering factors.
Increasing incidence of brain cancer and focus on precision medicine
Increasing incidence of Brain Cancer has resulted in upsurge the demand for brain cancer across the globe which is driving the market. In addition, increased focus on precision medicine is also fuelling the global brain tumor therapeutics market.
Few brain cancer specific drugs and high cost of treatment
Few brain cancer specific drugs and their high cost is acting as a restraint for Brain Tumor therapeutics market. Although various pharmaceutical companies are spending heavily on R&D activities which can bring more treatment options to the market in future.
North America to Dominate the Market
The Brain Tumor Therapeutics market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the Brain Tumor therapeutics market due to the increasing technological advancements and the rising incidence of brain cancer in the country. Asia-Pacific is also expected to propel the Brain Tumor therapeutics market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.
Key developments in the market
In January, 2018 iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.
In December, 2017, Diffusion Pharmaceuticals (DFFN) Launches Phase 3 Trial for Glioblastoma
Major key players: F. HOFFMAN LA-ROCHE LTD., MERCK, NOVARTIS, IMMUNOCELLULAR THERAPEUTICS, NOVOCURE, DELMAR PHARMACEUTICALS INC. MOLECULIN BIOTECH etc.
Reasons to purchase this report
Market analysis for the Global Brain Tumor Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.
Analyzing various perspectives of the company with the help of Porter's five forces analysis
The treatment type that is expected to dominate the market
Regions that are expected to witness fastest growth during the forecast period
Identify the latest developments, market shares and strategies employed by the major market players.
3 months analyst support along with the Market Estimate sheet in excel.
Customization of the report
This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
TABLE OF CONTENTS